The global asthma therapeutics market is expected to grow at growth rate of 1.9% to reach USD 24.8 billion by 2025.

Asthma and COPD conditions are a major burden on the economy of a nation, especially in countries such as the U.S., China and France. This is due to the rise in number of smokers and increasing pollution. This has fueled government initiatives to educate the people regarding awareness about asthma, and their management as well as funding by various government and non-government agencies, leading to drive the market growth. Other factors such as aging population, rise in healthcare expenditure, increasing research and development initiatives stimulated the market growth.  However, expiry of leading branded drugs such as Singulair (montelukast sodium), Symbicort (budesonide/formoterol fumarate), Advair (fluticasone propionate/salmeterol xinafoate),  and Xolair (omalizumab) is anticipated to hamper the market growth.

The global Asthma therapeutics market is segmented on the basis of drug class, product, route of administration and region. On the basis of drug class, the market is segmented into anti- inflammatory, bronchodilators and combination therapy. Anti- inflammatory drugs are expected to witness market growth owing to R&D developments pertaining to biologics. Patent expiration of anti- inflammatory drugs during the forecast period will have impact on the revenue generation.

On the basis of products offered by companies, the market is segmented into inhalers and nebulizers. Inhalers are most widely adopted owing to the patient compliance and ease of administration. They held the leading position in the market. Amongst inhalers, metered dose inhalers have been widely adopted due to their application in the long term therapy. Nebulizers are anticipated to grow at the highest CAGR during the forecast period.

On the basis of route of administration, the market is segmented into oral, inhaled and other routes. Inhaled route of administration accounted for the largest revenue in the year 2015. This is due to effective pharmacodynamics and pharmacokinetic actions upon administration of drug dose by this route. Oral route of administration is expected to emerge as the fastest growing market over the forecast period. Geographically, the market is represented as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America dominated the overall asthma therapeutics market in terms of revenue share in 2014 at over 50.0%.

Some of the key players in this industry include AstraZeneca Plc, Philips Healthcare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Sanofi-Aventis SA, CareFusion Corporation,  Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH and others.

KEY BENEFITS OF THE REPORT:

• Understanding of the strategies that are being adopted by the key players in this market to stay competitive
• Extensive analysis of the key players dominating the competitive landscape of this market
• In-depth analysis of the key factors are propelling the growth of the global market
• Detailed analysis of the geographic region that will witness the strongest growth
• Granular analysis of the current market scenario and the expected market grow

The scope of this report covers the market by its major segments, which include as follows:

Market Segmentation

MARKET, BY DRUG CLASS

• Anti-inflammatory
• Bronchodilators
• Combination Therapy

MARKET, BY PRODUCTS

• Inhalers
• Nebulizers

MARKET, BY ROUTE

• Oral
• Inhaled
• Subcutaneous
• Intravenous

MARKET, BY REGION

• North America
• Europe
• Asia Pacific
• Rest of the World

MARKET, BY COUNTRY

• Further Breakdown of The North America Market
  • U.S.
  • Canada
• Further Breakdown of The Europe Market
  • Germany
  • France
  • Rest of Europe
  • Further Breakdown of The APAC Market
    • India
    • China
    • Rest of APAC
  • Further Breakdown of The Rest of the World Market
    • Middle East and Africa
    • Latin America